Official-source baseline for Aardvark Therapeutics using SEC submissions, SEC XBRL companyfacts, FY2025 10-K, Q1 FY2026 10-Q, company-filed results releases, clinical-update 8-Ks, prospectus filings, and peer filings.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
